ANRO
Alto Neuroscience Inc.

1,108
Mkt Cap
$611.7M
Volume
91,613.00
52W High
$20.91
52W Low
$1.60
PE Ratio
-8.56
ANRO Fundamentals
Price
$19.69
Prev Close
$19.29
Open
$18.94
50D MA
$17.33
Beta
1.65
Avg. Volume
186,376.25
EPS (Annual)
-$2.50
P/B
4.80
Rev/Employee
$0.00
$47.22
Loading...
Loading...
News
all
press releases
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire·6d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Trading Down 6.6% - What's Next?
Alto Neuroscience (NYSE:ANRO) Stock Price Down 6.6% - Here's Why...
MarketBeat·11d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Trading Up 10% - Here's What Happened
Alto Neuroscience (NYSE:ANRO) Stock Price Up 10% - Here's Why...
MarketBeat·12d ago
News Placeholder
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...
Business Wire·16d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Trading 9.8% Higher - Should You Buy?
Alto Neuroscience (NYSE:ANRO) Trading Up 9.8% - Still a Buy...
MarketBeat·20d ago
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports...
MarketBeat·20d ago
News Placeholder
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...
Business Wire·26d ago
News Placeholder
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0%
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm...
MarketBeat·2mo ago
<
1
2
...
>

Latest ANRO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.